Transmucosal delivery of Docetaxel by mucoadhesive polymeric nanofibers

Figures & data

Table I. Optimization parameters and microscopic observations of different trials.

Formulation code	PVA concentration (% w/v)	Potential applied (KV)	Flow rate (ml/h)	TCD (cm)	Observations
R1	8	12	0.25	14	High density, non-continuous, thick, beads
R2	8	14	0.25	14	High density, continuous, no beads, thick
R3	8	16	0.25	14	High density, continuous, thin, no beads
R4	8	12	0.25	18	Low density, continuous, thin, beads
R5	8	14	0.25	18	Medium density, continuous, thick, no beads
R6	8	16	0.25	18	High density, non-continuous, beads, thin
R7	8	12	0.25	20	Low density, non-continuous, thin, no beads
R8	8	14	0.25	20	Medium density, continuous, thin, beads
R9	8	16	0.25	20	Medium density, continuous, thick, no beads

Figure 1. (a) SEM image of plain PVA nanofiber and (b) drug loaded nanofibers.

Figure 2. IR spectra of PVA polymer, drug (Docetaxel) and drug loaded nanofibers.

Figure 3. Percentage swelling index of unloaded and drug loaded nanofibers.

Figure 4. Drug release profile of the drug loaded Nanofibers in PBS 6.8.

Figure 5. Percentage viability between plain drug and the carrier system.

Figure 6. DSC of drug loaded nanofibers.

Figure 7. Permeability studies of drug loaded nanofibers.